Last $0.79 USD
Change Today -0.071 / -8.26%
Volume 224.4K
As of 8:10 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

tni biotech inc (TNIB) Snapshot

Open
$0.86
Previous Close
$0.86
Day High
$0.86
Day Low
$0.72
52 Week High
05/2/13 - $5.10
52 Week Low
03/19/14 - $0.57
Market Cap
66.6M
Average Volume 10 Days
65.5K
EPS TTM
--
Shares Outstanding
84.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TNI BIOTECH INC (TNIB)

Related News

No related news articles were found.

tni biotech inc (TNIB) Related Businessweek News

No Related Businessweek News Found

tni biotech inc (TNIB) Details

TNI BioTech, Inc., a specialty pharmaceutical company, develops therapeutic products for the treatment of cancer, HIV/AIDS, hospitalization related, and infectious diseases in the United States and internationally. The company offers IRT-101, an active immunotherapy systemic administration of methionine-enkephalin that works by activating a patient's immune system against infectious diseases and tumor cells. It also provides IRT-102, an adaptive immunotherapy for the treatment of various autoimmune diseases, such as Crohn's disease and multiple sclerosis. The company has strategic partnership with The Brewer Group, Inc. TNI BioTech, Inc. is based in Bethesda, Maryland.

12 Employees
Last Reported Date: 03/31/14

tni biotech inc (TNIB) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: $218.6K
President and Director
Total Annual Compensation: $16.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $5.0K
Chief Operating Officer and Director
Total Annual Compensation: $199.9K
Chief Science Officer and Director
Total Annual Compensation: $15.0K
Compensation as of Fiscal Year 2012.

tni biotech inc (TNIB) Key Developments

TNI BioTech, Inc. Auditor Raises 'Going Concern' Doubt

TNI BioTech, Inc. filed its 10-K on Mar 31, 2014 for the period ending Dec 31, 2013. In this report its auditor, Turner, Stone & Company, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

TNI BioTech, Inc. Signs Supplementary Cooperation Agreement on New Drug Methionine-Enkephalin with Hubei Qianjiang Pharmaceutical Co., Ltd

TNI BioTech, Inc. announced that it has signed a 'Supplementary Cooperation Agreement on New Drug Methionine-Enkephalin' with Hubei Qianjiang Pharmaceutical Co., Ltd. Following TNI BioTech's FDA meeting in August of 2013, in which the FDA approved TNI BioTech to study Methionine-Enkephalin in clinical trials for pancreatic cancer advancing TNI BioTech's path to End of Phase II and the possibility of Phase III studies, Qianjiang has engaged in significant market research and pre-trials on pharmaceutical and pharma-toxicology studies, which suggest initial positive results. In order to accelerate clinical trials in America and China, Qianjiang and TNI BioTech have agreed that Qianjiang will immediately start clinical trials in China. According to the previous agreements and as expanded by this latest Agreement, Qianjiang will provide funding for such studies and TNI BioTech will provide all its research materials, data, and results in America to Qianjiang and Qianjiang and TNI BioTech will seek registration for MENK in China. If and when manufacturing approval is achieved from the Chinese Government, Qianjiang will produce and sell MENK in China subject to the terms of a further agreement with TNI BioTech. IRT-101 (MENK) is an active immunotherapy with MENK for patients with deficient functioning of the immune system. It works by restoring the patient's immune functions and by activating the lymphocytes to attack cancer cells and infectious diseases, such as HIV/AIDS. This is accomplished because MENK binds to opioid receptors on both immune cells and on cancer cells, which directly inhibits the growth of cancer cells and increases the number and functions of T-cells, NK cells, NK-T cells, and gamma/delta T-cells. These cells then destroy infective organisms and tumor cells while simultaneously inhibiting the ability of T regulatory (Treg) cells to block the functions of anti-cancer or anti-infectious disease lymphocytes.

The Brewer Group Announces Strategic Partnership with TNI BioTech, Inc

The Brewer Group, Inc. announced a new strategic partnership with TNI BioTech, Inc. Through a variety of business development strategies including exclusive access to its extensive global reach, TBG will provide tailored services including investment banking advisory as well as government, investor relations and marketing support to TNIB in an effort to offer affordable treatment technologies to those in need for as low as $1.00 per day in numerous markets throughout the world. TNIB's products, technologies and patents are designed to harness the power of the immune system to improve the treatment of cancer and infections, such as HIV/AIDS and autoimmune diseases. TBG will use their established international network and deep relationships to help accelerate and advance TNIB's growth in various international markets as well as assist with global distribution while continuing TBG's mission of "A Global Vision with a Social Focus." The Brewer Group and TNIB are fully committed to continuing their efforts toward establishing oncology clinics in regions where cancer care is currently virtually non-existent. In other areas where there is already an existing foundation, the companies will work to strengthen the pre-existing care through donations of additional medicines and offering expertise and advice. As cancer is now the leading cause of death worldwide and particularly affects developing countries, the two organizations hope to provide an innovative solution for underserved communities and individuals who cannot afford the quality care that they need. The partnership will specifically focus on global expansion using TBG's exclusive network and established relationships with key international decision makers spanning government development agencies, financial institutions, private equity firms, corporations, NGO's and major distribution partners in numerous continents including throughout the Caribbean, Latin America and in various regions of Africa.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TNIB:US $0.79 USD -0.071

TNIB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TNIB.
View Industry Companies
 

Industry Analysis

TNIB

Industry Average

Valuation TNIB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TNI BIOTECH INC, please visit www.tnibio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.